
Vertex Pharmaceuticals Incorporated
VRTXHealthcare|Biotechnology|US
$547.09
+4.59 (+0.85%)
DCF Value
$349.13
Tangible Book / Share
$39.31
Graham Number
$170.60
Cash / Share
$24.87
Next Earnings Report
Feb 11, 2027
EPS est. $4.23 · Revenue est. $3.50B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (25)
Dec 2026
Est. completion
P1Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
NCT07868926n=8
Dec 2026
Est. completion
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572n=401
Jan 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06696443n=455
Jan 2027
Est. completion
Feb 2027
Est. completion
P1P2Myotonic Dystrophy Type 1 (DM1)
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
NCT06185764n=47
Mar 2027
Est. completion
Mar 2027
Est. completion
P1Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
NCT07792408n=148
Mar 2027
Est. completion
P1P2Type 1 Diabetes
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
NCT05791201n=7
Mar 2027
Est. completion
P2Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860n=300
Apr 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419n=734
Apr 2027
Est. completion
P3Cystic Fibrosis
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183n=297
May 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908n=1,100
Jun 2027
Est. completion
P3Sickle Cell Disease
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649n=13
Jun 2027
Est. completion
P3Beta-Thalassemia
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT05477563n=26
Jun 2027
Est. completion
P1Cystic Fibrosis
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
NCT07437105n=160
Jul 2027
Est. completion
P1Cystic Fibrosis
Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
NCT07283770n=152
Jul 2027
Est. completion
P2Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037n=26
Sep 2027
Est. completion
P3Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
NCT06460506n=50
Nov 2027
Est. completion
P3Beta-Thalassemia
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195n=16
Dec 2027
Est. completion
P3Diabetes Mellitus, Type 1
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
NCT04786262n=57
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P3
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257Recent Press Releases
Vertex Reports Third Quarter 2026 Financial Results
Nov 2, 2026 · Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026
Oct 23, 2026 · Business Wire
Vertex Appoints Daniel Brennan to its Board of Directors
Oct 20, 2026 · Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Oct 9, 2026 · Business Wire
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
Oct 7, 2026 · Business Wire
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Sep 22, 2026 · Business Wire
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Sep 1, 2026 · Business Wire
Vertex to Participate in Upcoming September Investor Conferences
Aug 26, 2026 · Business Wire
SEC Filings (44)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 3, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Nov 2, 2026 | 8-K | Material event | DocumentIndex |
| Oct 20, 2026 | 8-K | Material event | DocumentIndex |
| Sep 1, 2026 | 8-K | Material event | DocumentIndex |
| Aug 4, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 3, 2026 | 8-K | Material event | DocumentIndex |
| Jul 7, 2026 | 8-K | Material event | DocumentIndex |
| May 14, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 14, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 13, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| May 13, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| May 13, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| May 13, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| May 13, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| May 13, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| May 13, 2026 | S-8 POS | Employee stock plan | DocumentIndex |
| May 13, 2026 | S-8 | Employee stock plan | DocumentIndex |
| May 13, 2026 | 8-K | Material event | DocumentIndex |
| May 5, 2026 | 10-Q | Quarterly report | DocumentIndex |
| May 4, 2026 | 8-K | Material event | DocumentIndex |
| Apr 30, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 29, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 29, 2026 | 8-K | Material event | DocumentIndex |
| Apr 2, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 2, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 2, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Mar 31, 2026 | 8-K | Material event | DocumentIndex |
| Mar 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 13, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 12, 2026 | 8-K | Material event | DocumentIndex |
| Feb 12, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Nov 4, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Nov 3, 2025 | 8-K | Material event | DocumentIndex |
| Aug 5, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Aug 4, 2025 | 8-K | Material event | DocumentIndex |
| May 19, 2025 | 8-K | Material event | DocumentIndex |
| May 14, 2025 | 8-K | Material event | DocumentIndex |
| May 13, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| May 6, 2025 | 10-Q | Quarterly report | DocumentIndex |
| May 5, 2025 | 8-K | Material event | DocumentIndex |